Latest Financial Results
Q3 2018
Quarterly Results
Ended Jul 31, 2018
Stock Information
Symbol
ANIXPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.
Latest News & Events
Anixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek™ Artificial Intelligence based Cancer Detection Technology
Read More...Anixa Biosciences Appoints Leading Researchers in Immuno-Oncology to its Scientific Advisory Board
Read More...Anixa Biosciences to Present at Artificial Intelligence Conference
Read More...Cancer Fact: Approximately 40 million mammograms are conducted annually.